Synapticure, a telemedicine company focused on neurodegenerative disease, announced it is partnering with the ALS Association to offer Synapticure’s telehealth platform as a supplement to in-person care at ALS Certified Treatment Centers of Excellence and Recognized Treatment Centers.
Synapticure is a neurology-focused telehealth company that specializes in neurodegenerative diseases. It provides...
Researchers from the Commonwealth Scientific and Industrial Research Organisation, in partnership with the Queensland University of Technology, have developed what could be the world's first AI-based benchmark for measuring brain atrophy.
WHAT IT'S ABOUT
They used AI to develop a set of artificial MRI brain images with predefined signs of neurodegeneration in the cortex region, an area of the...
Fujifilm Corporation has developed AI technology that can predict whether patients with mild cognitive impairment will progress to Alzheimer's disease within two years.
According to a press statement, the AI Technology for AD Progression Prediction has been found to have high generalisability, predicting patients who would progress to AD with high accuracy, even for subjects from different...
Cionic scored FDA 510(k) clearance for its Neural Sleeve, a legging that provides electrical stimulation so people with foot drop and muscle weakness can walk more easily.
The leg-worn device, which officially received the green light from the agency in mid-February, is aimed at people with neurological conditions like multiple sclerosis, stroke and cerebral palsy. The sleeve's electrical...
A Boston-based startup is looking to help treat neurodegenerative disease with a smartphone-based digital therapeutic called Neuroglee.
This morning the startup got a boost when it closed a $10 million Series A round led by Openspace Ventures with participation from EDBI, Eisai Co and individual investors.
“Various techniques have been demonstrated to slow or improve cognitive impairment in...
Yesterday Cognito Therapeutics, a startup using visual and auditory stimulation to treat neurodegenerative disorders, announced Phase 2 trial results suggesting its gamma frequency neuromodulation therapy slowed declines in memory and cognition among mild-to-moderate Alzheimer's disease patients.
The OVERTURE study, a multi-center, randomized controlled trial, enrolled 76 such patients aged 50...
